ClinicalTrials.Veeva

Menu
S

Sherman Clinical Research | Sherman, TX

Research site
(Unclaimed)

Site insights

Top conditions

Top treatments

Vonoprazan
Ziltivekimab
Ensifentrine
Salmeterol
LY3502970
SAR440340
LY3298176
Lanifibranor
JTT-861
Stiolto®

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

11 of 18 total trials

A Phase 3 Study Evaluating Efficacy and Safety of Lanifibranor Followed by an Active Treatment Extension in Adult Patients With (NASH) and Fibrosis Stages F2 and F3 ( NATiV3 )

This Phase 3 study is conducted to evaluate lanifibranor in adults with NASH and liver fibrosis histological stage F2 or F3

Enrolling
NASH - Nonalcoholic Steatohepatitis
Drug: Placebo
Drug: IVA337

The study is being done to see if ziltivekimab can be used to treat participants living with heart failure and inflammation. Participants will either...

Enrolling
Systemic Inflammation
Heart Failure
Drug: Placebo
Drug: Ziltivekimab
Locations recently updated

This study will be done to see if ziltivekimab can be used to treat people living with heart failure and inflammation. Participants will either get z...

Enrolling
Heart Failure
Drug: Placebo
Drug: Ziltivekimab

The main purpose of this study is to determine safety and efficacy of orforglipron compared with insulin glargine in participants with type 2 diabete...

Enrolling
Chronic Kidney Disease
Overweight
Drug: Orforglipron
Drug: Insulin Glargine

The main purpose of this study is to assess the efficacy and safety of Tirzepatide (LY3298176) in participants with heart failure with preserved ejec...

Active, not recruiting
Heart Failure With Preserved Ejection Fraction (HFpEF)
Obesity
Other: Placebo
Drug: Tirzepatide

The purpose of this study is to demonstrate the efficacy of 9-valent extraintestinal pathogenic Escherichia coli vaccine (ExPEC9V) compared to placeb...

Enrolling
Invasive Extraintestinal Pathogenic Escherichia Coli Disease (IED) Prevention
Biological: ExPEC9V
Other: Placebo

The purpose of this study is to evaluate the efficacy of lepodisiran in reducing cardiovascular risk in participants with high lipoprotein(a) who hav...

Enrolling
Atherosclerotic Cardiovascular Disease (ASCVD)
Elevated Lp(a)
Drug: Lepodisiran Sodium
Drug: Placebo

This study will be a placebo-controlled, double-blind, randomized, phase 3 study in participants with Atherosclerotic Cardiovascular Disease (ASCVD)...

Active, not recruiting
Atherosclerotic Cardiovascular Disease
Drug: Obicetrapib
Drug: Placebo

This study will evaluate the efficacy, safety, tolerability and pharmacokinetics of JTT-861 administered once daily for 12 weeks in subjects with hea...

Enrolling
Chronic Heart Failure
Drug: JTT-861 Capsules
Drug: Placebo Capsules

Study CKJX839B12302 is a pivotal Phase III trial to evaluate the benefits of inclisiran on major adverse cardiovascular (MACE) events in participants...

Active, not recruiting
Atherosclerotic Cardiovascular Disease
Drug: Placebo
Drug: Inclisiran sodium 300 mg

Primary Objective:Evaluate the efficacy of itepekimab compared with placebo on the annualized rate of acute moderate-or-severe COPD exacerbations in...

Active, not recruiting
Chronic Obstructive Pulmonary Disease
Drug: Placebo
Drug: Itepekimab SAR440340

Trial sponsors

Lilly logo
Novo Nordisk logo
Phathom Pharmaceuticals logo
V
Akros Pharma logo
B
Boehringer Ingelheim logo
I
Janssen (J&J Innovative Medicine) logo
N

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems